CS-101 is Shanghai-based CorrectSequence's lead candidate, which it is developing for treating sickle-cell disease and ...

The firm began a Phase II study of evorpacept in HER2-positive breast cancer patients and began testing a higher dose of ALX2004 in a separate Phase I trial.

The therapy, A2B543, will be added as an arm to the ongoing Phase I/II EVEREST-2 trial, which is testing CAR T-cell products developed using A2's Tmod platform. According to A2, the Tmod platform ...

Lexeo says the collaboration will accelerate the development of an unnamed preclinical cardiac gene therapy target.

NEW YORK – Sarepta Therapeutics on Wednesday said it submitted an application to regulators in New Zealand, seeking to begin a first-in-human trial of SRP-1005, the siRNA drug it's developing for ...

With this new grant, nonprofit A Race Against Blindness has provided a total of $5.1 million to advance AXV-101.

The new Phase III study will test calderasib in a chemo-free regimen for G12C-mutated patients regardless of PD-L1 status.

The collaboration will support development of Ascidian's RNA exon editor therapy, ACDN-01, for treating the rare genetic eye disease.

The companies struck a multi-year strategic collaboration, under which GSK will have access to Helix's GenoSphere cohorts.

The deal brings Dark Blue's preclinical oncology products, including an MLLT1/3-targeted agent for leukemias, into Amgen's portfolio.

The companies have proposed a strategic partnership in which Ikarovec will continue to develop its IKAR-003 gene therapy using VectorBuilder's tech.

Researchers will test whether the company's Genomic Prostate Score assay predicts disease progression and outcomes in a prospective cohort.